Related Experiment Video

Updated: Nov 15, 2025

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.3K

Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

Shuichi Matsumura1, Mikihito Nakamori1,2, Toshiaki Tsuji1

  • 1Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.

Oncotarget
|March 4, 2021
PubMed

Insights

This study developed an oncolytic herpes simplex virus (HSV) armed with suppressor of cytokine signaling 3 (SOCS3) to combat gastric cancer. The engineered virus, T-SOCS3, demonstrated enhanced replication and potent cancer cell destruction in preclinical models.

Area of Science:

  • Oncolytic virotherapy
  • Cancer biology
  • Virology

Background:

  • Gastric cancer remains a significant global health challenge.
  • Oncolytic herpes simplex virus (HSV) shows promise for cancer treatment.
  • Targeting viral replication and immune evasion is crucial for effective virotherapy.

Purpose of the Study:

  • To engineer and evaluate an oncolytic HSV expressing suppressor of cytokine signaling 3 (SOCS3) for gastric cancer treatment.
  • To assess the efficacy of the armed oncolytic HSV (T-SOCS3) against gastric cancer cells ex vivo.
  • To determine if SOCS3 arming enhances viral replication and oncolytic activity.

Main Methods:

  • Construction of a third-generation oncolytic HSV (T-SOCS3) armed with SOCS3 using a bacterial artificial chromosome (BAC) system.
  • Evaluation of viral replication and oncolysis of T-SOCS3 in human gastric cancer cell lines (MKN1) ex vivo.
  • Assessment of T-SOCS3's efficacy on human gastric cancer specimens.

Main Results:

  • T-SOCS3 exhibited enhanced viral replication compared to a non-armed control (T-01).
  • T-SOCS3 demonstrated potentiated oncolytic effects against MKN1 gastric cancer cells, which are resistant to T-01.
  • T-SOCS3 induced significant destruction within human gastric cancer specimens.

Conclusions:

  • Armed oncolytic HSVs expressing SOCS3 represent a promising therapeutic strategy for gastric cancer.
  • T-SOCS3 enhances viral replication and cell-killing efficacy, offering a potential new treatment avenue.
  • Further investigation into SOCS3-armed oncolytic HSV is warranted for gastric cancer therapy.
Keywords:
gastric cancerherpes simplex virusoncolytic virus

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

12.9K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.7K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
850
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.8K